Claims
- 1. A pharmaceutical composition for treating patients with human immunodeficiency virus (HIV) infection comprising effective amounts of a mixture of aqueous extracts obtained from:an entire plant of Herba Hedyotidis diffusae (diffuse hedyotis); a rhizome of Rhizoma Bistortae (bistort rhizome); a rhizome of Rhizoma Polygoni Cuspidati (giant knotweed rhizome); a ripe fruit of Fructus Schisandrae (Chinese magnoliavine fruit); a rhizome of Rhizoma Menispermi (Asiatic moonseed rhizome); a root of Radix Scutellariae (baical skullcap root); bovine biliary powder; a root tuber of Radix Curcumae (tumeric root-tuber); a ripe fruit of Fructus Crataegi (hawthorn fruit); a root of Radix Notoginseng (sanqi); a ripe fruit of Fructus Lycii (barbary wolfberry fruit); a root of Radix Scorphulariae (figwort root); a root of Radix Angelicae sinensis (Chinese angelica); and a root of Radix Astragali (milkvetch root), wherein said pharmaceutical composition does not contain Radix ginseng rubra (red ginseng).
- 2. The pharmaceutical composition according to claim 1, wherein said aqueous extract of said ingredients is a water extract of said ingredients.
- 3. The pharmaceutical composition according to claim 2, wherein said water extract is further filtered and condensed to form a condensate.
- 4. The pharmaceutical composition according to claim 1, wherein said diffuse hedyotis, said bistort rhizome; said giant knotweed rhizome, said Chinese magnoliavine fruit, said Asiatic moonseed rhizome, said baical skullcap root, said bovine biliary powder, said tumeric root-tuber, said hawthorn fruit, said sanqi, said barbary wolfberry fruit, said figwort root, said Chinese angelica, and said milkvetch root are at a weight ratio of about 4:3:1:2:1:1:0.1: 1:2:1:3:2:1:2.
- 5. The pharmaceutical composition according to claim 1, wherein said pharmaceutical composition is in a form of an intravenous injection solution.
- 6. The pharmaceutical composition according to claim 1, wherein said pharmaceutical composition is in a form of powders.
- 7. The pharmaceutical composition according to claim 6, wherein said powders are encapsulated.
- 8. A method for preparing the pharmaceutical composition according to claim 1 comprising:grinding and mixing said diffuse hedyotis, said bistort rhizome, said giant knotweed rhizome, said Chinese magnoliavine fruit, said Asiatic moonseed rhizome, said baical skullcap root, said bovine biliary powder, said tumeric root-tuber, said hawthorn fruit, said sanqi, said barbary wolfberry fruit, said figwort root, said Chinese angelica, and said milkvetch root to form a mixture; boiling said mixture in water to form a water extract; filtering said water extract to collect a filtrate; and concentrating said filtrate to form a condensate; wherein said condensate is dissolved in a solution to form an injection solution or sprayed dried to form powders.
- 9. The method according to claim 8, wherein said filtrate is about 1.4 fold of the volume of said condensate.
- 10. The method according to claim 8, wherein said intravenous injection solution is further diluted to about 1:5 to 1:10 by volume of a 5% glucose solution.
- 11. The method according to claim 8, wherein said powders are mixed with starch and encapsulated.
- 12. A method for treating patients with HIV comprising:intravenously administering to said patients an effective amount of said condensate of said pharmaceutical composition according to claim 3.
- 13. The method according to claim 12, wherein said injection solution is in a dosage amount of about 1 to 10 g of said condensate per day.
- 14. The method according to claim 13, wherein said injection solution is in the dosage amount of about 2 to 6 g of said condensate per day.
- 15. A method for treating patients with HIV infection comprising:intravenously administering an injection solution and orally administering a capsule to said patients; wherein said injection solution and said capsule each comprise said condensate of said pharmaceutical composition according to claim 3.
- 16. The method according to claim 15, wherein said injection solution is in a dosage amount of about 1 to 10 g of said condensate per day.
- 17. The method according to claim 16, wherein said injection solution is in the dosage amount of about 2-6 g of said condensate per day.
- 18. The method according to claim 15, wherein said capsule is in a dosage amount of about 0.1 to 2 g of said condensate of said pharmaceutical composition per serving and at about 2-4 times a day.
CROSS-REFERNCE TO RELATED APPLICATION
The present application is a continuation-in-part (CIP) of U.S. patent application Ser. No. 09/906,791 filed on Jul. 18, 2001, now U.S. Pat. No. 6,455,078 which in turn claims the priority of U.S. Provisional Application No. 60/240,963 filed on Oct. 18, 2000. Both U.S. priority applications are herein incorporated by reference.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
5178865 |
Ho et al. |
Jan 1993 |
A |
5837257 |
Tsai et al. |
Nov 1998 |
A |
5989556 |
Tsai et al. |
Nov 1999 |
A |
Foreign Referenced Citations (4)
Number |
Date |
Country |
8800048 |
Oct 1988 |
CN |
1151312 |
Jul 1996 |
CN |
1148983 |
May 1997 |
CN |
1151312 |
Jun 1997 |
CN |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/240963 |
Oct 2000 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09/906791 |
Jul 2001 |
US |
Child |
10/208050 |
|
US |